ClinicalTrials.gg
RecruitingNCT07484087Updated Mar 19, 2026

Ablation Compare With Surgery for Early Breast Cancer

An interventional study of breast conserving surgery and cryo-thermal ablation in Breast Cancer, Early Stage and Hormone Receptor Positive, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Breast Neoplasms by Peking University People's Hospital — 17 open to participants now, 18 under way, none of them phase 3. Breast Neoplasms · Peking University People's Hospital.

Planned enrollment
5th of 17
264 · median 200
Started
2026
with 6 others
No phase
7 of 32
4 open now
Primary completion
2028-12
later than 12 of 17 live
Registered
26th of 32
by date

Among the 32 studies in Breast Neoplasms by Peking University People's Hospital, this one is the 5th largest by planned enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2026, is one of 7 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 26th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 32 studies in Breast Neoplasms by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by Peking University People's Hospital, or all of them as a file.
02

Study summary

Breast-conserving surgery has been widely used in clinical practice, but surgical incisions still impact postoperative patient satisfaction with breast appearance. The development of tumor ablation technologies has introduced new possibilities for breast cancer surgical treatment. The hybrid cryo-thermal ablation system, an advanced minimally invasive tumor treatment device independently developed in China, employs a combined approach of deep cryoablation and high-intensity heating for therapy and has been approved for treating solid tumors, including breast cancer.

This study is a prospective, single-center, randomized controlled trial. Eligible patients with newly diagnosed early-stage breast cancer treated at the Breast Center of Peking University People's Hospital will be enrolled and randomized in a 1:1 ratio to receive either hybrid cryo-thermal ablation (experimental group) or breast-conserving surgery (control group). Data collected will include:

Baseline clinicopathological characteristics, Surgical details (operation time, intraoperative/postoperative complications, etc.), Peripheral blood lymphocyte distribution, Treatment efficacy (ipsilateral breast tumor recurrence rate, disease-free survival, overall survival), Aesthetic outcomes (BREAST-Q score).

Primary endpoint:

Ipsilateral breast local recurrence rate,

Secondary endpoints:

Safety (incidence of adverse events assessed by CTCAE criteria), Disease-free survival and overall survival, Quality of life assessment (breast satisfaction),

Exploratory endpoints:

Pathological response of ablated tumor tissue, Correlation analysis between postoperative imaging (MRI/ultrasound) features and recurrence risk.

03

Conditions studied

  • Breast Cancer
  • Early Stage
  • Hormone Receptor Positive
  • Ablation

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Age ≥50 Years 2.Unifocal disease (single tumor) confirmed by ultrasound, MRI, or mammography. Ultrasound visibility: Essential for precise intraoperative ablation targeting. 3. Confirmed Invasive Ductal Carcinoma (IDC)。Diagnostic Method: Core needle (CNB) confirming IDC.

    4.Histologic Grade: G1 or G2; ER/PR-positive and -negative. 5.TNM stage: IA. Tumor Size: ≤2 cm; Lymph Node Status: Clinically \& radiologically negative (no palpable/imaging-detected axillary involvement).

    6.Written consent for clinical trial participation and acceptance of random assignment

Exclusion criteria

Exclusion Criteria:

  • 1.Extensive intraductal component (EIC) suggested by imaging or pathology. 2.Invasion of adjacent skin or muscle. 3.Prior anticancer treatment for the current disease, including but not limited to chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. 5.Refusal to undergo breast-conserving surgery. 6.Pregnancy or lactation. 7.Previous radiotherapy to the affected breast or other to radiotherapy. 8.Concurrent untreated or severe systemic diseases, 9.Known allergy, intolerance, or contraindications to cryotherapy (e.g., cryoglobulinemia, implanted electronic devices). 10.Inability to comply with follow-up or refusal of therapy. 11.Vulnerable populations, including individuals with neurological disorders, cognitive impairment, or critical illness.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    breast conserving surgery

    According to the 《Chinese Breast Cancer Diagnosis and Treatment Guidelines》, standard breast-conserving surgery (BCS) was performed, with pathologically confirmed negative margins.

    Procedure: breast conserving surgery

  • Experimental
    cryo-thermal ablation

    Under ultrasound guidance, the tumor location and boundaries were precisely marked to ensure the ablation zone covered at least 5 mm beyond the tumor edge, achieving complete oncological safety.

    Procedure: cryo-thermal ablation

Interventions

  • Procedurebreast conserving surgery

    According to the 《Chinese Breast Cancer Diagnosis and Treatment Guidelines》, standard breast-conserving surgery (BCS) was performed, with pathologically confirmed negative margins.

  • Procedurecryo-thermal ablation

    Real-time ultrasound imaging to confirm tumor size and shape. Mark the ablation target zone, including the 5-mm peripheral margin. Ablation Procedure Step 1: Probe Insertion Under ultrasound guidance, insert the cryo-thermal ablation probe into the tumor center. Step 2: Dual-Cycle Ablation (Freeze-Heating-Freeze) First Freeze Cycle: Duration: 10-15 minutes. Temperature: Rapid cooling to -196°C (liquid nitrogen). Endpoint: Ice ball fully envelops the tumor + 5-mm margin (confirmed by ultrasound). Heating Phase: Temperature: Rapid heating to 80°C. Duration: 5-10 minutes (thawing and thermal damage enhancement). Second Freeze Cycle: Repeat freezing to ensure complete tumor destruction.

06

What researchers measure

Primary outcomes

  1. Ipsilateral Breast Tumor Recurrence Rate

    The time from the date of surgery to the date of ipsilateral breast tumor recurrence, with the occurrence of ipsilateral breast tumor recurrence as the event.

    Time frame: 3 years

Secondary outcomes

  1. complication rate

    intraoperative Complications: Bleeding, vascular/nerve injury. Postoperative Complications: Infection, hematoma, skin frostbite (cryoablation-specific), breast deformity, sensory abnormalities. Grading: Recorded per CTCAE v5.0 (e.g., Grade 1: mild; Grade 3: severe requiring intervention).

    Time frame: 3 months

  2. Disease-Free Survival

    Time from study enrollment to the first occurrence of: Ipsilateral locoregional recurrence. Contralateral breast cancer. Distant metastasis, Death from any cause.

    Time frame: 3 years

  3. overall survival

    Time from study enrollment to death from any cause.

    Time frame: 5 years

  4. Quality of Life (QoL)

    Tool: BREAST-Q (validated patient-reported outcome measure) Phychosocial well-being scale, satisfaction with breasts scale Domains Evaluated: Breast aesthetics (appearance/satisfaction post-treatment). Psychosocial/sexual well-being. Physical discomfort.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 35 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 19, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2031
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07484087
Responsible party
Shu Wang (director of breast center, Peking University People's Hospital) — Principal investigator
First posted
Mar 19, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Mar 19, 2026

Study contacts

yuan peng, doctor
Contact
13671287670@163.com
86+13671287670
shu wang, doctor
study director · Peking University People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion